Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment

Yuxiao Song(Wuhan University), Bicheng Zhang(University of Electronic Science and Technology of China), Bo Zhu(Huaian First People’s Hospital), Qi Xie(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Wang(Shenzhen Bao'an District People's Hospital), Yang Fu(First Affiliated Hospital of Zhengzhou University)
Frontiers in Immunology
August 25, 2020
10.3389/fimmu.2020.01956
Cited by 256

Related Papers

T-cell exhaustion in the tumor microenvironment
|Cell Death and Disease|2015|1.1k
Clinical characteristics of 82 cases of death from COVID-19
|PLoS ONE|2020|594
Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19
|Frontiers in Molecular Biosciences|2020|497
Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019
|Clinical Infectious Diseases|2020|458
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417